Markets:

Overview

News

Currencies

International

Treasuries

Lucid Diagnostics Inc. - Common Stock (NQ:LUCD)

1.050 -0.030 (-2.78%)

Streaming Delayed Price Updated: 4:00 PM EDT, Jun 29, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Lucid Diagnostics Inc. - Common Stock

< Previous 1 2 3 4 5 Next >

PAVmed Digital Health Subsidiary Veris Health Launches Veris Cancer Care Platform

December 15, 2022

From PAVmed Inc.

Via Business Wire

Lucid Diagnostics Selected as Finalist for Medtech Company of the Year 2022 by Medical Device + Diagnostic Industry

December 08, 2022

From Lucid Diagnostics Inc.

Via Business Wire

Earnings Scheduled For May 11, 2022 ↗

May 11, 2022

Companies Reporting Before The Bell • Great Elm Capital (NASDAQ:GECC) is expected to report earnings for its first quarter.

Via Benzinga

Lucid Diagnostics Presents Real-World EsoCheck Data at the American Association for Cancer Research

December 01, 2022

From Lucid Diagnostics Inc.

Via Business Wire

PAVmed Provides Business Update and Third Quarter 2022 Financial Results

November 15, 2022

From PAVmed Inc.

Via Business Wire

Lucid Diagnostics Provides Business Update and Third Quarter 2022 Financial Results

November 14, 2022

From Lucid Diagnostics Inc.

Via Business Wire

Lucid Diagnostics Commences Production of EsoCheck Devices with High-Volume Manufacturer

November 09, 2022

From Lucid Diagnostics Inc.

Via Business Wire

Lucid Diagnostics to Participate in Canaccord Genuity’s MedTech, Diagnostics and Digital Health & Services Forum

November 10, 2022

From Lucid Diagnostics Inc.

Via Business Wire

Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on November 14, 2022

November 02, 2022

From Lucid Diagnostics Inc.

Via Business Wire

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

August 24, 2022

Via Benzinga

Lucid Diagnostics Provides Business Update and Preliminary Second Quarter 2022 Financial Results

August 15, 2022

From Lucid Diagnostics Inc.

Via Business Wire

Lucid Diagnostics Launches Stage II Lucid Test Center Expansion in California, Texas, Florida, and Ohio

August 11, 2022

From Lucid Diagnostics Inc.

Via Business Wire

Newly Published American Gastroenterological Association Clinical Practice Update Supports Esophageal Precancer Screening Using Lucid Diagnostics’ EsoGuard® and EsoCheck® Technologies

August 04, 2022

From Lucid Diagnostics Inc.

Via Business Wire

Lucid Diagnostics to Hold a Business Update Conference Call on August 15, 2022

August 01, 2022

From Lucid Diagnostics Inc.

Via Business Wire

Lucid Diagnostics’ Laboratory Executes Four New Participating Provider Agreements

August 02, 2022

From Lucid Diagnostics Inc.

Via Business Wire

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

July 05, 2022

Gainers NeuroBo Pharmaceuticals (NASDAQ:NRBO) stock rose 14.5% to $0.53 during Tuesday's after-market session. The company's market cap stands at $14.0 million.

Via Benzinga

Lucid Diagnostics to Participate in the Canaccord 42nd Annual Growth Conference and the 7th Annual Needham Med Tech & Diagnostics 1x1 Conference

July 18, 2022

From Lucid Diagnostics Inc.

Via Business Wire

Lucid Diagnostics Provides Business Update and Preliminary First Quarter 2022 Financial Results

May 11, 2022

From Lucid Diagnostics Inc.

Via Business Wire

PAVmed and Lucid Diagnostics Chairman & CEO Lishan Aklog, M.D. Named Top 50 Healthcare Technology CEO

May 13, 2022

From PAVmed Inc.

Via Business Wire

Lucid Diagnostics to Hold a Business Update Conference Call on May 11, 2022

April 25, 2022

From Lucid Diagnostics Inc.

Via Business Wire

Lucid Diagnostics’ Laboratory Executes Participating Provider Agreement with MediNcrease Health Plans

May 09, 2022

From Lucid Diagnostics Inc.

Via Business Wire

How Is The Market Feeling About Lucid Diagnostics Inc. - Common Stock? ↗

March 30, 2022

Lucid Diagnostics Inc. - Common Stock's (NASDAQ:LUCD) short percent of float has fallen 4.35% since its last report. The company recently reported that it has 378.70 thousand...

Via Benzinga

PAVmed Provides Business Update and Preliminary Fourth Quarter and Full Year 2021 Financial Results

March 29, 2022

From PAVmed Inc.

Via Business Wire

Lucid Diagnostics Provides Updates on Newly Published Esophageal Precancer Clinical Guideline and Proposed Medicare Local Coverage Determination

April 04, 2022

From Lucid Diagnostics Inc.

Via Business Wire

10 Biggest Price Target Changes For Tuesday ↗

March 29, 2022

BTIG cut the price target on NeoGenomics, Inc. (NASDAQ: NEO) from $35 to $28. NeoGenomics shares fell 29.2% to $12.60 in pre-market trading.

Via Benzinga

Lucid Diagnostics Provides Business Update and Preliminary Fourth Quarter and Full Year 2021 Financial Results

March 28, 2022

From Lucid Diagnostics Inc.

Via Business Wire

Lucid Diagnostics to Participate in the Needham 21st Annual Healthcare Conference

March 30, 2022

From Lucid Diagnostics Inc.

Via Business Wire

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

March 24, 2022

Gainers BiondVax Pharmaceuticals (NASDAQ:BVXV) shares moved upwards by 55.5% to $2.13 during Thursday's pre-market session. The market value of their outstanding...

Via Benzinga

PAVmed Subsidiary Lucid Diagnostics Announces Launch of VA EsoGuard® Study

March 24, 2022

From Lucid Diagnostics Inc.

Via Business Wire

PAVmed Subsidiary Lucid Diagnostics Launches Next Phase of Lucid Test Centers

March 23, 2022

From Lucid Diagnostics Inc.

Via Business Wire

< Previous 1 2 3 4 5 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.